AI filing briefs · archive

8-K filings in January 2024, explained

73 material Form 8-K filings that 66 companies we cover made with the SEC in January 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 73 briefs match

newest first · times in ET

ECHOEchoStar CORP Jan 10, 8:36 PM ET

EchoStar moves DISH spectrum and $4.7 billion receivable into new subsidiaries

Neutral restructuring Written later 5.02 8.01

EchoStar announced it completed a series of transactions after its merger with DISH Network. DISH Network transferred unencumbered wireless spectrum licenses to a new EchoStar subsidiary, and a $4.7 billion Tranche A receivable is now owed to an EchoStar subsidiary. The filing says these steps are meant to give the company more strategic and financing flexibility, and EchoStar has hired advisers to evaluate strategic alternatives.

DISH Network transferred spectrum licenses including AWS-4, H-Block, CBRS and C-Band to EchoStar Wireless Holding L.L.C.
Tranche A receivable, valued at approximately $4.7 billion, was assigned to EchoStar Intercompany Receivable Company L.L.C.
DBS Subscriber Subsidiary holds approximately 3.0 million DISH TV subscribers.
On January 8, 2024, Timothy Messner resigned from the DISH DBS board and Tom Ortolf was appointed to it.

Read the filing on SEC.gov ↗

TGTXTG THERAPEUTICS, INC. Jan 10, 7:37 AM ET

TG Therapeutics Reports Preliminary 2023 BRIUMVI Revenue of $89 Million

Neutral earnings Written later 1.01 7.01

TG Therapeutics preliminarily reported unaudited U.S. BRIUMVI net product revenue of approximately $40 million for the fourth quarter of 2023 and $89 million for the full year, with a year-end 2023 cash position of approximately $215 million. It also set 2024 targets of $220 million to $260 million in full-year BRIUMVI revenue and about $250 million in operating expense, and disclosed a January 7, 2024 license for azer-cel from Precision BioSciences. The filing does not give prior-period comparisons, so the figures alone do not show whether results improved.

Preliminary U.S. BRIUMVI net product revenue of approximately $40 million for Q4 2023 and $89 million for full year 2023, unaudited
2024 targets: $41 million to $46 million for Q1 BRIUMVI revenue and $220 million to $260 million for full year; full-year operating expense of approximately $250 million
Azer-cel license with Precision BioSciences dated January 7, 2024: $7.5 million upfront and up to $288 million in additional milestone payments, plus royalties

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.